Whether the CD34 þ and CD3 þ cell doses in allogeneic HSCT should be estimated using actual (ABW) or ideal (IBW) body weight has never been definitively determined. We have shown that CD34 þ cell doses based upon IBW are better predictive of engraftment after autologous and allogeneic HSCT. Sixty-three patients undergoing reduced-intensity HSCT after a uniform preparative regimen were evaluated to determine the effect of cell dose. ABW and IBW were 45-147 kg (median 79) and 52-85 kg (median 67) respectively. The ABW-IBW difference was À24% to þ 133% (median þ 16%); nine patients were 45% underweight and 41 were 45% overweight. The CD34 þ cell dose (10 6 /kg) was 1.4-11.8 (median 5) by IBW and 1.2-9.3 (median 4.5) by ABW. The CD3 þ cell dose (10 8 /kg) was 0.9-14.9 (median 3) by IBW and 0.7-19.7 (median 2.7) by ABW. While CD34 þ and CD3 þ cell doses based upon IBW were found to affect transplant-related mortality, and disease-free and overall survival significantly, those based on ABW were either not predictive of outcome or the differences were of borderline significance. We suggest using IBW rather than ABW to calculate cell doses for HSCT; for statistical analyses and for clinical practice if a specific cell dose is being targeted.
Introduction
CD34 þ cell content of the graft affects the outcome of blood and marrow transplants significantly. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] With the exception of one study, 14 higher cell doses have been associated with lower transplant-related mortality (TRM) and better disease-free survival (DFS) in all reports. Cell dose has been measured in terms of total nucleated cells (TNC) [1] [2] [3] [4] 6, [8] [9] [10] 12, 13, 15 or CD34 þ cells 7, 11, 14 per kg body weight of the patient.
However, whether actual (ABW) or ideal (IBW) body weight has been used to calculate this cell dose has not been specified in any of the reports except one of ours 11 where ABW was used. We have always used ABW in our studies 1, 6, 8, 10, 11 and in clinical practice, as has a recent large study 15 that was devoted exclusively to investigating the impact of cell dose on outcome (Andrea Bacigalupo MD, personal communication). A survey of colleagues in the field revealed that everyone uses ABW for cell dose calculations.
There is evidence that IBW is a better predictor than ABW of cell dose adequacy as measured by recovery of neutrophils after autologous 16, 17 as well as allogeneic 18 HSCT. However, there are no data on whether cell dose based on IBW or ABW is a better predictor of TRM and survival -more relevant outcomes than hematologic recovery -after allogeneic HSCT. We studied the outcome of 63 adult patients undergoing reduced-intensity HSCT (RI-HSCT) from adult donors to study the effect of the CD34 þ and CD3 þ cell doses, and the basis for calculating them.
Patients and methods
Records of 63 consecutive patients undergoing RI-HSCT using a uniform, melphalan-based conditioning regimen were reviewed after approval from the institutional review board. The treatment period was March 2001 to May 2004. Table 1 shows patient characteristics. All patients had hematologic malignancies requiring allogeneic HSCT, and were felt to be unsuitable for CI-HSCT because of advanced age, poor performance status, compromised organ function, concomitant active medical conditions, or a combination of these features. Of the 40 sibling donors, 37 were matched at six of six HLA antigens tested (A, B, DR) using low-resolution DNA typing, and three were mismatched at a single antigen. Of the 23 donors identified through the National Marrow Donor Program, 19 were matched at 10 of 10 alleles tested (A, B, C, DRB1, DQB1) using high-resolution DNA typing, and four were mismatched at a single allele. Donors were aged 24-69 years (median 46).
Conditioning regimen
Patients who had relapsed after a previous autograft received 100 mg/m 2 melphalan followed 24 h later by donor stem cell infusion. Those not autografted previously received 50 mg/kg cyclophosphamide with mesna 24 h before melphalan. The drugs were dosed based on the actual body weight if it was less than the ideal weight, and on adjusted body weight (ideal þ 25% of the difference between actual and ideal) if the actual weight was greater than the ideal. IBW (kg) was calculated by a standard formula 19 using sex and height: 50 þ {2.3 Â (Height in inchesÀ60)} for males and 45.5 þ {2.3 Â (Height in inchesÀ60)} for females.
Stem cell collection and graft characteristics All donors underwent leukapheresis after stimulation with granulocyte colony-stimulating factor (G-CSF), and bloodderived stem cells were used exclusively for transplantation. The CD34 þ cell dose measurement was based upon the patient's IBW. Based upon our previous experience in myeloablative HSCT, 11 3 Â 10 6 CD34 þ cells/kg was considered a minimum acceptable dose from sibling donors. Siblings underwent leukapheresis on more than one occasion if needed to meet the minimum cell dose requirement. While the same cell number was requested of the unrelated donors, the final yield was beyond our control and was below the minimum acceptable in four cases. All unrelated donor stem cells were used fresh, and all sibling donor stem cells had been collected and cryopreserved before starting the conditioning regimen.
Graft-versus-host disease prophylaxis
Patients allografted from HLA-identical sibling donors received cyclosporine from day À1 at the dose of 3 mg/kg IV as a continuous intravenous infusion. This was switched to PO as soon as engraftment had occurred, and oral intake was consistent and predictable. Patients allografted from mismatched sibling donors or unrelated donors (irrespective of HLA match grade) received tacrolimus from day À1 at the dose of 0.05 mg/kg as a continuous intravenous infusion. This was changed to PO as soon as engraftment had occurred and oral intake was adequate. The calcineurin inhibitor was tapered from the 7th week onwards with a view to discontinuing it completely between 100 and 150 days post transplant in the absence of clinically significant graft-versus-host disease (GVHD) requiring immunosuppressive therapy. All patients also received mycophenolate mofetil 1000 mg twice daily orally; from day 21 to 150 in recipients of matched sibling cells and from day 1 to 150 in the others. GVHD was treated with corticosteroids in addition to continuation of the prophylactic agents, and more agents were added as needed based upon response.
Supportive therapy
All patients received ciprofloxacin or levofloxacin from day 0 to day 60, valaciclovir 500 mg thrice daily from day À1 to 1 month beyond discontinuation of immunosuppression, itraconazole liquid 200 mg twice daily from day 0 to 1 month beyond discontinuation of immunosuppression, and monthly inhaled pentamidine or thrice-weekly trimethoprim-sulfamethoxazole from the time of engraftment to 1 month beyond discontinuation of immunosuppression. Itraconazole was switched to voriconazole if patients received corticosteroids for the treatment of GVHD. Owing to concerns about toxicity, no myeloid growth factors were used routinely post transplant but G-CSF 300-480 mg was started daily if the total leukocyte count was p0.2 Â 10 9 /l on day 14.
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Statistical analysis Data were analyzed using SPSS for Windows (Release 10.0.5) as of 30 June 2005 (minimum follow-up of 41 year). The w 2 test (with Yates correction as needed) was used to compare categoric variables and the Wilcoxon rank-sum test was used to compare continuous variables. The probabilities of disease-free survival (DFS) and overall survival (OS) were estimated by the Kaplan-Meier method, and compared using the log-rank test. Cumulative incidence of TRM and relapse was estimated using each type of event as a competing risk for the other. Cumulative incidence of acute and chronic GVHD was estimated using TRM and relapse as competing events.
Two patients dying in CR of causes obviously unrelated to the transplant and the underlying disease (cardiac arrhythmia and exacerbation of pre-existing chronic obstructive pulmonary disease at 15.4 and 26.8 months, respectively) were censored at the time of death for computing OS and DFS, and were considered to have experienced competing events for calculating the cumulative incidence of TRM and relapse.
Since 3 Â 10 6 /kg was the predefined CD34 þ cell threshold, o3 vs X3 was one of the thresholds chosen for comparison. Based upon our preliminary experience 21 and some suggestion that very high CD34 þ cell doses may be detrimental, [22] [23] [24] we also compared the outcome of /kg) with those getting a cell dose that was outside this narrow limit. Since there was no predefined CD3 þ cell dose limit, o3 vs X3 Â 10 8 /kg (close to the median) was chosen for comparison.
Results
Sixteen patients died of transplant-related causes at 0.4 to 30.9 months (median 3.7). The causes of death were multiorgan toxicity/failure (n ¼ 7), GVHD (n ¼ 6), renal failure (n ¼ 1), aspiration pneumonia (n ¼ 1), and mucormycosis (n ¼ 1).
Effect of cell dose on TRM As Table 2 shows, patients receiving a low CD34 þ cell dose had significantly greater TRM; the difference being more marked when calculated by IBW than by ABW. Additionally, the outcome of patients who received a dose that was adequate based upon IBW but low based upon ABW appeared to be similar to those who received an adequate cell dose. Similarly, there was trend towards lower TRM amongst patients receiving an 'optimal' CD34 þ cell dose based upon IBW compared to the others. However, there was no significant TRM difference when the 'optimal' cell dose range was based upon ABW.
Similarly, as Table 3 shows, patients receiving a high CD3 þ cell dose had significantly greater TRM; the difference being more marked when calculated by IBW than by ABW. The outcome of patients who received a dose that was high based upon IBW but low based upon ABW appeared to be similar to those who received a high cell dose.
Survival
Thirty-five patients were found to have recurrent or persistent disease at 0.5 to 30.1 months (median 3.7). There was no effect of cell doses on relapse rates (data not shown). Eight relapsed patients were alive in CR 12.2 to 29.9 months after relapse (median 24.6), whereas 27 died of relapsed disease or consequences of subsequent therapy. The 2-year probabilities of OS and DFS were 36% (95% CI: 24-48%) and 21% (95% CI: 11-31%) respectively. Figures 1-4 show the effect of the CD34 þ cell dose and CD3 þ cell dose groups on OS -and depict significance with IBW but not with ABW. The outcomes for DFS were similar (data not shown).
Discussion
Our findings suggest that for different CD34 þ and CD3 þ cell dose thresholds, values based upon IBW appear to be Actual or ideal body weight to calculate cell doses? S Singhal et al better correlated with outcome after RI-HSCT than those based upon ABW. These findings are also in keeping with our previous observations that CD34 þ cell doses based upon IBW correlate better with the speed of neutrophil recovery after autologous 17 as well as allogeneic 18 HSCT. This has some practical implication in individuals who are donating stem cells for overweight patients with a large disparity between ABW and IBW. Such a healthy donor may be spared an unnecessary apheresis procedure if the number of cells collected has reached the target by IBW but not by ABW.
There may be a more important concern, especially when using blood-derived stem cells. The Genoa group, using bone marrow and the number of nucleated cells, has shown that the outcome keeps improving as the cell dose keeps increasing. 15 However, there is evidence that the infusion of a very high number of CD34 þ cells from the peripheral blood may be associated with a higher risk of GVHD. [22] [23] [24] Przepiorka et al. 22 found that CD34 þ cell doses over 8 Â 10 6 /kg were associated with a significantly increased risk of acute GVHD. In a subsequent report, 23 it was shown that prior acute GVHD was a significant risk factor for the development of extensive chronic GVHD along with lack of methotrexate-containing GVHD prophylaxis, and the best outcome was seen amongst patients receiving o8 Â 10 6 /kg CD34 þ cells and methotrexate-containing GVHD prophylaxis. The Seattle group 24 found that CD34 cell doses over 8 Â 10 6 /kg were associated with a significantly increased risk of extensive chronic GVHD. None of these three reports specified whether the cell dose was based upon IBW or ABW.
In the absence of a multivariable analysis in a larger number of patients, our findings cannot be used to conclusively support the contention that cell dose is relevant in RI-HSCT. Indeed, while the infused cell dose has been found to be consistently important in influencing survival in the setting of marrow transplants, its importance in blood stem cell transplantation is unclear. This may be in part to the near-universal use of ABW as the basis for calculation rather than IBW. Based upon our findings, future analyses should be based upon IBW to see if cell dose is relevant in blood stem cell transplantation. If it is shown to be relevant, it will become important to collect and transplant an optimum number of stem cells to eliminate this potentially modifiable/controllable factor as a variable that may affect outcome adversely. Figure 4 The effect of the CD34 þ cell dose based on ideal body weight on overall survival (P ¼ 0.56).
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